OTC ZOVIRAX ADVISORY COMMITTEE REVIEW
This article was originally published in The Tan Sheet
Executive Summary
OTC ZOVIRAX ADVISORY COMMITTEE REVIEW is now expected to take place late this year or the beginning of 1995 in order to give burroughs Wellcome time to submit data that addresses issues raised at FDA's public hearing on May 19. Burroughs Wellcome's NDA to support OTC marketing of Zovirax (acyclovir) to treat recurrent genital herpes was tentatively set to be reviewed by FDA's Nonprescription Drugs and Antiviral Drugs Advisory Committees on July 28.